At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
CS1001biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma(ENKTL)
In Brief
A Phase 2 clinical trial evaluating CS1001 for Extranodal Natural Killer/T-Cell Lymphoma. Completed, enrolled 80 participants across 17 sites.
Detailed Summary
This is a multicenter, single-arm, phase II study to evaluate the efficacy and safety of CS1001 monotherapy for Relapsed or Refractory Extranodal Natural Killer/ T Cell Lymphoma (ENKTL)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
20192020202120222023202420252026
Enrollment StartJun 2018
First PostedJul 2018
Primary CompletionMar 2023
TodayJul 2026
First PostedJul 23, 2018
Enrollment StartJun 12, 2018
Primary CompletionMar 20, 2023
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 7.9 years ago
Interventions
CS1001biological
monoclonal antibody